SUMO2/3/4 Antibody [Alexa Fluor™ Plus 405]

• Reactivity: Hu, Mu
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor Plus 405

SUMO2/3/4 Antibody [Alexa Fluor™ Plus 405] Summary

• Specificity: Detects endogenous human and mouse proteins modified with SUMO2, 3, or 4 in Western blots. Because of the high level of sequence homology, this antibody has equivalent reactivity to SUMO2, SUMO3, and SUMO4 based in Western blots with recombinant SUMO protein. Cross-reactivity to recombinant human SUMO1 was minimal in Western blots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for SUMO2/3/4 Antibody [Alexa Fluor™ Plus 405]

• HSMT3;Small ubiquitin-related modifier;Small ubiquitin-related modifier 2;Smt3A;SMT3B;SMT3H2;SUMO3
• SUMO2/3/4

Background

Small Ubiquitin-like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation. Unlike ubiquitination, which targets proteins for degradation, sumoylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. All SUMO proteins share the conserved ubiquitin domain and the C-terminal diglycine cleavage/attachment site. Human SUMO2, also known as Sentrin2 and SMT3B is synthesized as a 95 amino acid (aa), 11 kDa propeptide that contains a two aa C-terminal prosegment, and an 18 aa N-terminal protein interacting region (aa 33‑50). Following prosegment cleavage, the C-terminal glycine is enzymatically attached to a lysine on a target protein. Human SUMO2 shares 100% sequence identity to SUMO-2 from mouse. SUMO2 also has very high sequence homology to SUMO3 and SUMO4, 86 % and 85%, respectively. SUMO2 shares only 44% sequence identity to SUMO1.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.